INDIGO’s assay kits and services can provide valuable information for your NAFLD/NASH research. Whether you are interested in a single-receptor assay or a full-panel study, we can help you obtain the data you need quickly.


Receptors for NAFLD/NASH Research

Understanding the mechanisms underlying the involvement of nuclear receptors in the pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD) or Non-Alcoholic Steatohepatitis (NASH) may offer targets for the development of new treatments for this liver disease. The most common nuclear receptors used in drug and treatment discovery are ligand-activated nuclear receptors, including peroxisome proliferator-activated receptor alpha (PPARα), pregnane X receptor (PXR), and constitutive androstane receptor (CAR), which were first identified as key regulators of the responses against chemical toxicants. Numerous studies using mouse disease models and human samples have revealed critical roles for these receptors and others, such as PPARβ/δ, PPARγ, farnesoid X receptor (FXR), and liver X receptors (LXR), in maintaining nutrient/energy homeostasis in part through modulation of the gut-liver-adipose axis.

NAFLD is associated with altered nuclear receptor function and perturbations along the gut-liver axis. These perturbations include obesity, abnormal hepatic lipid metabolism, increased inflammation, and insulin resistance. Nuclear receptors are essential to understanding the physiology and pathology of liver diseases like NAFLD/NASH, as they are at the crossroads of metabolism, inflammation, and regeneration. Modulation of nuclear receptors has been shown to reduce hepatic steatosis, inflammation, insulin resistance, fibrosis, and obesity, making them attractive – and effective – therapeutic targets.


Indigo Assays for NAFLD/NASH Research

INDIGO Biosciences offers assays for receptors that are implicated as promising therapeutic targets for NAFLD/NASH:


Non-Alcoholic Fatty Liver Disease (NAFLD) is characterized by liver inflammation and the buildup of extra fat in liver cells not caused by excessive alcohol consumption. The liver naturally contains some fat, however, when the weight of the fat content of the liver is more than 5-10%, the condition is known as fatty liver (steatosis). NAFLD is the most common liver disorder in developed countries with more than 100 million adults and children affected in the United States alone. NAFLD occurs in people of all races and ethnicities, though research shows it to be most common in those of Latin American descent. Non-Alcoholic Steatohepatitis (NASH) is the most extreme form of NAFLD, and is a major cause of cirrhosis of the liver and liver cancer.

The majority of people with NAFLD have no symptoms, though some may experience fatigue, dull upper right quadrant abdominal discomfort, and/or mild jaundice. Diagnosis typically occurs following abnormal liver function tests from routine blood test. Common findings are elevated liver enzymes and a liver ultrasound showing steatosis. A liver biopsy is the only widely accepted test for definitively distinguishing NASH from other forms of liver disease. Current estimates indicate that about 20 percent of people with NAFLD have NASH.

Certain factors - including unknown etiology, complex patho-physiology, and high treatment costs - make understanding how associated nuclear receptors respond and react key to further development.

Related Products and Services

A scientist dispenses a sample into a microcentrifuge tube within a BCL2 cabinet.

Drug Discovery Assay Kits

Get fast, clear, reproducible results from INDIGO’s all-inclusive reporter assay kits. No cell culture required!

Automatic pipette dispensing into a 96 well plate

Reporter Assay Services

Rapidly gain a clear overview of chemicals, pharmaceutical compounds, or environmental samples on key biological receptors.

Loading test samples into a multiwell reaction plate

Custom Assay Development

Contact our team of specialists and design custom assays tailored to your needs.

Related Information

Nuclear Receptors and Their Classifications


How Nuclear Receptor Profiling Can Determine the Fate of Your Compounds


How to Develop Testing Strategy for EDCs in Water Resources


Profiling Drug Activity of Human and Ortholog Xenobiotic-Sensing Receptors: PXR, CAR, AhR, and FXR - INDIGO Biosciences


Regulation of Steatosis in upcyte® Hepatocytes by Nuclear Receptor Agnostics


Correlation Between Cytochrome P450 Inducers and Nuclear Receptor Activation - a Screening Approach - INDIGO Biosciences


Human CYP2B6 Produces Oxylipins from Polyunsaturated Fatty Acids and Reduces Diet-Induced Obesity

Disruption of the Tumor Suppressor-Like Activity of Aryl Hydrocarbon Receptor by Arsenic in Epithelial Cells and Human Lung Cancer

Effects-Based Monitoring of Bioactive Compounds Associated with Municipal Wastewater Treatment Plant Effluent Discharge to the South Platte River, Colorado, USA

What Our Customers Say

"They’re one of the best suppliers that we’ve worked with by far. They were very communicative as far as getting us the reagents we needed quickly."


Principal Scientist

"In terms of the CROs that I typically deal with, INDIGO is a lot more responsive than some of the other ones…"



"The overall experience went smoothly, and I got valuable data that helped me advance several molecules through the discovery pipeline."


Associate Director

Interested to know more about nuclear receptor assays?

Questions/Request a Quote